More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study ...

“Daratumumab-based quadruplet regimens are redefining frontline treatment in multiple myeloma, offering the potential for deeper, more durable responses from the start, bringing patients closer ...

“Daratumumab-based quadruplet regimens are redefining frontline treatment in multiple myeloma, offering the potential for deeper, more durable responses from the start, bringing patients closer to ...

Data from the Phase 3 CEPHEUS study show daratumumab-VRd significantly reduced the risk of progression or death by 49 percent vs VRd alone in transplant-ineligible newly diagnosed patients 2 ...

Send an email to George. The White House’s delivery to the House of Representatives of a package that would codify some of the Department of Government Efficiency’s cuts into law was greeted ...

escalated his attacks Wednesday on President Donald Trump’s massive tax and immigration package, urging lawmakers to “KILL the BILL.” His exhortation on social media came hours after the ...

The idea is to make the cuts more permanent by having Congress pass what’s known as a “rescissions” package. This would codify the DOGE cuts into law, so that they can’t be reversed by the ...

Discovery gave a thumbs down to the company’s executive compensation for 2024 — multi-million dollar paydays led by CEO David Zaslav’s $51.9 million package. The vote, informally called say ...

The CEPHEUS trial shows D-VRd regimen significantly improves outcomes in transplant-ineligible NDMM patients, with higher MRD negativity and complete response rates compared to VRd. Median PFS was ...